The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 17, 2026

Filed:

Nov. 18, 2024
Applicant:

Lipocine, Inc., Salt Lake City, UT (US);

Inventors:

Nachiappan Chidambaram, Salt Lake City, UT (US);

Mahesh V. Patel, Salt Lake City, UT (US);

Jonathan Ogle, Salt Lake City, UT (US);

Kongnara Papangkorn, Salt Lake City, UT (US);

Samuel Akapo, Salt Lake City, UT (US);

Joel Frank, Salt Lake City, UT (US);

Benjamin J. Bruno, Salt Lake City, UT (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/57 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01);
U.S. Cl.
CPC ...
A61K 31/57 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2031 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/2095 (2013.01); A61K 9/4825 (2013.01); A61K 9/4833 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 9/4875 (2013.01);
Abstract

Disclosed is a method and a brexanolone containing oral composition for treating CNS disorders such as depression. An embodiment of the invention comprises orally administering a brexanolone containing composition to a subject having a CNS disorder. The composition and methods disclosed herein exhibit effective oral absorption/bioavailability and a predetermined ratio of bioavailability in a fed state administration relative to a fasted state administration.


Find Patent Forward Citations

Loading…